Similar Breast Cancer Risk in Women Older Than 65 Years Initiating Glargine, Detemir, and NPH Insulins Similar Breast Cancer Risk in Women Older Than 65 Years Initiating Glargine, Detemir, and NPH Insulins - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes (...) to an error Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation Diabetes Care Actions 2020 Feb 19 [Online ahead of print] Similar Breast Cancer Risk in Women Older Than 65 Years Initiating Glargine, Detemir, and NPH Insulins , , , , , , , , , , Affiliations Expand Affiliations 1 Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver

Sotagliflozin with insulin for treating type 1 diabetes Sotagliflozin with insulin for treating type 1 diabetes T echnology appraisal guidance Published: 12 February 2020 www.nice.org.uk/guidance/ta622 © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Your responsibility Your responsibility The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available (...) an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Sotagliflozin with insulin for treating type 1 diabetes (TA622) © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 21Contents Contents 1 Recommendations 4 2 Information about sotagliflozin 6 3 Committee discussion 7 Clinical management 7 Experience of people

Efficacy and safety of empagliflozin as add-on to insulin in Japanese patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial Efficacy and Safety of Empagliflozin as Add-On to Insulin in Japanese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard (...) collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation Diabetes Obes Metab Actions 2019 Nov 6 [Online ahead of print] Efficacy and Safety of Empagliflozin as Add-On to Insulin in Japanese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial

Similar glycaemic control and less hypoglycaemia during active titration after insulin initiation with glargine 300 units/mL and degludec 100 units/mL: A subanalysis of the BRIGHT study Similar Glycaemic Control and Less Hypoglycaemia During Active Titration After Insulin Initiation With Glargine 300 units/mL and Degludec 100 units/mL: A Subanalysis of the BRIGHT Study - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features (...) Create a new collection Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation Diabetes Obes Metab Actions 2019 Oct 23 [Online ahead of print] Similar Glycaemic Control and Less Hypoglycaemia During Active Titration After Insulin Initiation

Randomized Study to Evaluate the Impact of Telemedicine Care in Patients With Type 1 Diabetes With Multiple Doses of Insulin and Suboptimal HbA1c in Andalusia (Spain): PLATEDIAN Study Randomized Study to Evaluate the Impact of Telemedicine Care in Patients With Type 1 Diabetes With Multiple Doses of Insulin and Suboptimal HbA 1c in Andalusia (Spain): PLATEDIAN Study - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome (...) collection Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation Diabetes Care Actions , 43 (2), 337-342 Feb 2020 Randomized Study to Evaluate the Impact of Telemedicine Care in Patients With Type 1 Diabetes With Multiple Doses of Insulin

Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial To investigate the efficacy, safety, and tolerability of oral semaglutide added to insulin with or without metformin.Patients with type 2 diabetes uncontrolled on insulin with or without metformin were randomized to oral semaglutide 3 mg (N = 184), 7 mg (N = 182), or 14 mg (N = 181) or to placebo (N = 184) in a 52-week, double (...) . 7.1% with placebo; mostly mild to moderate).Oral semaglutide was superior to placebo in reducing HbA1c and body weight when added to insulin with or without metformin in patients with type 2 diabetes. The safety profile was consistent with other glucagon-like peptide 1 receptor agonists.© 2019 by the American Diabetes Association.

Faster Compared With Standard Insulin Aspart During Day-and-Night Fully Closed-Loop Insulin Therapy in Type 1 Diabetes: A Double-Blind Randomized Crossover Trial We evaluated the safety and efficacy of day-and-night fully closed-loop insulin therapy using faster (Faster-CL) compared with standard insulin aspart (Standard-CL) in young adults with type 1 diabetes.In a double-blind, randomized, crossover trial, 20 participants with type 1 diabetes on insulin pump therapy (11 females, aged 21.3 (...) as the primary end point.The proportion of TIR was similar for both arms: 53.3% (83% overnight) in Faster-CL and 57.9% (88% overnight) in Standard-CL (P = 0.170). The proportion of time in hypoglycemia <70 mg/dL was 0.0% for both groups. Baseline-adjusted interstitial prandial glucose increments 1 h after meals were greater in Faster-CL compared with Standard-CL (P = 0.017). The gaps between measured plasma insulin and estimated insulin-on-board levels at the beginning, at the end, and 2 h after the exercise

Systematic literature review and network meta-analysis of sodium-glucose co-transporter inhibitors vs metformin as add-on to insulin in type 1 diabetes To identify and synthesize phase 3 and phase 4 randomized controlled trials (RCTs) of sodium-glucose co-transporter (SGLT) inhibitors and metformin as adjuncts to insulin in type 1 diabetes (T1DM) using network meta-analysis (NMA).A systematic literature review (SLR) identified relevant RCTs of ≥12 Weeks duration. MEDLINE, Embase, the Cochrane (...) Library and grey literature were searched through October 2018. NMAs indirectly compared SGLT inhibitors and metformin for change from baseline in HbA1c, weight, total daily insulin dose and systolic blood pressure at Week 24 to 26 and Week 52. Safety outcomes were also explored.Nine trials (N = 6780) were included in the SLR. NMAs indicated that all therapies performed better than placebo for the efficacy outcomes at both time points. Compared with metformin at Week 24 to 26, the SGLT inhibitors

Comparison of lixisenatide in combination with basal insulin vs other insulin regimens for the treatment of patients with type 2 diabetes inadequately controlled by basal insulin: Systematic review, network meta-analysis and cost-effectiveness analysis To evaluate the comparative efficacy and safety of lixisenatide combined with basal insulin (BI) vs intensive premix insulin (premix), BI plus prandial insulin with the main meal (basal-plus) or progressively covering all meals (basal-bolus (...) treated with different strategies.Eight RCTs were finally included. Lixisenatide plus BI showed a similar reduction in HbA1c from baseline compared with premix, basal-plus and basal-bolus. There were significant differences in the change of body weight in favour of lixisenatide plus BI compared with the three insulin regimens. The risk of symptomatic hypoglycaemia of lixisenatide plus BI was significantly lower compared with premix and basal-bolus. Lixisenatide plus BI was cost-effective compared

Divergent Hypoglycemic Effects of Hepatic-Directed Prandial Insulin: A Six-Month Phase 2b Study in Type 1 Diabetes Hepatic-directed vesicle insulin (HDV) uses a hepatocyte-targeting moiety passively attaching free insulin, improving subcutaneous insulin's hepatic biodistribution. We assessed HDV-insulin lispro (HDV-L) versus insulin lispro (LIS) in type 1 diabetes (T1D).Insulin Liver Effect (ISLE-1) was a 26-week, phase 2b, multicenter, randomized, double-blind, noninferiority trial.Among 176 (...) randomized participants (HDV-L n = 118, LIS n = 58), the difference in change from baseline A1C was 0.09% (95% CI -0.18% to 0.35%), confirming noninferiority (prespecified margin ≤0.4%). Overall, there were no statistically significant differences between treatments for hypoglycemia or insulin dosing. However, baseline A1C modified the treatment group effect (interaction P < 0.001) on clinically apparent hypoglycemia designated by treatment-blinded investigators as severe. Thus, at higher baseline A1C

The relationships between hemoglobin and insulin resistance, glucose effectiveness, and first- and second-phase insulin secretion in adult Chinese. We denote the four major factors related to the development of type 2 diabetes (T2D) as "diabetes factor" (DF); increased insulin resistance (IR); decreased glucose effectiveness (GE); and the first-and-second-phase of insulin secretion (FPIS, SPIS). The level of hemoglobin (Hb) was found to be related to IR and FPIS, but no-known studies focused (...) , it was IR. Both phases of insulin secretion had relatively weaker relationships than IR and GE.

Non-Insulin Therapies versus Prandial Insulin for Adults with Type 2 Diabetes: Clinical Effectiveness, Cost-Effectiveness, and Guidelines Non-Insulin Therapies versus Prandial Insulin for Adults with Type 2 Diabetes: Clinical Effectiveness, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Non-Insulin Therapies versus Prandial Insulin for Adults with Type 2 Diabetes: Clinical Effectiveness, Cost-Effectiveness, and Guidelines Non-Insulin Therapies versus Prandial (...) Insulin for Adults with Type 2 Diabetes: Clinical Effectiveness, Cost-Effectiveness, and Guidelines Last updated: April 24, 2019 Project Number: RB1329-000 Product Line: Research Type: Drug Report Type: Summary of Abstracts Result type: Report Question What is the comparative clinical effectiveness of non-insulin therapies versus prandial insulin for the treatment of adults with type 2 diabetes who are receiving basal insulin? What is the comparative cost-effectiveness of non-insulin therapies versus

Long-Acting Insulin Analogues versus Human NPH Insulin for Adults with Type 2 Diabetes and Unresponsive to Non-insulin Therapies: Clinical Effectiveness, Cost-Effectiveness, and Guidelines Long-Acting Insulin Analogues versus Human NPH Insulin for Adults with Type 2 Diabetes and Unresponsive to Non-insulin Therapies: Clinical Effectiveness, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Long-Acting Insulin Analogues versus Human NPH Insulin for Adults with Type 2 (...) Diabetes and Unresponsive to Non-insulin Therapies: Clinical Effectiveness, Cost-Effectiveness, and Guidelines Long-Acting Insulin Analogues versus Human NPH Insulin for Adults with Type 2 Diabetes and Unresponsive to Non-insulin Therapies: Clinical Effectiveness, Cost-Effectiveness, and Guidelines Last updated: May 3, 2019 Project Number: RB1331-000 Product Line: Research Type: Drug Report Type: Summary of Abstracts Result type: Report Question What is the comparative clinical effectiveness of long

Standardized Insulin Order Sets for Insulin-Dependent Diabetic Adults in the Community Setting: Clinical Evidence and Guidelines Standardized Insulin Order Sets for Insulin-Dependent Diabetic Adults in the Community Setting: Clinical Evidence and Guidelines | CADTH.ca Find the information you need Standardized Insulin Order Sets for Insulin-Dependent Diabetic Adults in the Community Setting: Clinical Evidence and Guidelines Standardized Insulin Order Sets for Insulin-Dependent Diabetic Adults (...) in the Community Setting: Clinical Evidence and Guidelines Last updated: May 10, 2019 Project Number: RA1029-000 Product Line: Research Type: Drug Report Type: Reference List Result type: Report Question What is the clinical evidence for standardized insulin order sets for diabetic adults who are dependent on insulin in the community setting? What are the evidence-based guidelines for standardized insulin order sets for diabetic adults who are dependent on insulin in the community setting? Key Message

Insulin degludec + liraglutide (Xultophy) - Diabetes mellitus, Type 2 insulin degludec + liraglutide | CADTH.ca Find the information you need insulin degludec + liraglutide insulin degludec + liraglutide Last Updated: October 3, 2019 Result type: Reports Project Number: SR0599-000 Product Line: Generic Name: insulin degludec + liraglutide Brand Name: Xultophy Manufacturer: Novo Nordisk Canada Inc. Indications: Diabetes mellitus, Type 2 Manufacturer Requested Reimbursement Criteria 1 (...) : To be reimbursed as an adjunct to lifestyle modifications to improve glycemic control in adults with type 2 diabetes mellitus when oral glucose-lowering medications combined with basal insulin, or basal insulin alone do not provide adequate glycemic control. Submission Type: New Combination Project Status: Active Biosimilar: No Fee Schedule: Schedule A The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH

Hybrid Closed Loop Insulin Delivery Systems: Clinical Effectiveness Hybrid Closed Loop Insulin Delivery Systems: Clinical Effectiveness | CADTH.ca Find the information you need Hybrid Closed Loop Insulin Delivery Systems: Clinical Effectiveness Hybrid Closed Loop Insulin Delivery Systems: Clinical Effectiveness Last updated: September 17, 2019 Project Number: RB1396-000 Product Line: Research Type: Devices and Systems Report Type: Summary of Abstracts Result type: Report Question What (...) is the clinical effectiveness of hybrid closed-loop insulin delivery systems in patients with type 1 diabetes? Key Message Three randomized controlled trials were identified regarding the clinical effectiveness of hybrid closed-loop insulin delivery systems in patients with type 1 diabetes. Files Rapid Response Summary of Abstracts Published : September 17, 2019 Related Content Follow us: © 2019 Canadian Agency for Drugs and Technologies in Health Get our newsletter:

Concentrated Human Insulin U-500: Pharmacology and Prospective Utilization Concentrated Human Insulin U-500: Pharmacology and Prospective Utilization | CADTH.ca Find the information you need Concentrated Human Insulin U-500: Pharmacology and Prospective Utilization Concentrated Human Insulin U-500: Pharmacology and Prospective Utilization Last updated: January 15, 2019 Project Number: HE0009-000 Product Line: Technology Review Result type: Report A concentrated solution (500 units/mL (...) ) of regular biosynthetic human insulin (U-500), marketed under the trade name Entuzity (Eli Lilly), was recently approved in Canada for adults and children with diabetes mellitus who require more than 200 units of insulin per day. The pharmacological properties (pharmacokinetics and pharmacodynamics) of this product may differ from the various U-100 insulins on the market. This project will review the data comparing the properties of these formulations and discuss clinical implications. It will also study

Injection ports for the subcutaneous administration of insulin in people with diabetes Insulin injection ports - Health Technology Wales > Insulin injection ports Insulin injection ports Topic Status Complete Injection ports for the subcutaneous administration of insulin in people with diabetes. Summary Health Technology Wales researchers searched for evidence on the use of needle-free injection systems as a way of administering insulin to treat diabetes mellitus. HTW’s Assessment Group

Dapagliflozin with insulin for treating type 1 diabetes Dapagliflozin with insulin for treating Dapagliflozin with insulin for treating type 1 diabetes type 1 diabetes T echnology appraisal guidance Published: 28 August 2019 www.nice.org.uk/guidance/ta597 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guidance represent the view of NICE, arrived (...) . Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Dapagliflozin with insulin for treating type 1 diabetes (TA597) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 24Contents Contents 1 Recommendations 4 2 Information about dapagliflozin 6 3

Efficacy and safety of linagliptin to improve glucose control in older people with type 2 diabetes on stable insulin therapy: A randomized trial To assess the addition of linagliptin as an alternative to insulin uptitration in older people with type 2 diabetes on stable insulin therapy.This phase 4, randomized, multicentre, double-blinded, placebo-controlled, 24-week study recruited individuals on stable insulin, with baseline HbA1c 7.0%-10.0%, aged ≥60 years and body mass index ≤45 kg/m2 (...) , including clinically important hypoglycaemia (blood glucose <54 mg/dL) or severe hypoglycaemia.Addition of linagliptin improves glucose control without an excess of hypoglycaemia in older patients with type 2 diabetes on stable insulin therapy.© 2019 John Wiley & Sons Ltd.